Welcome to our dedicated page for Biocryst Pharmaceuticals SEC filings (Ticker: BCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCryst Pharmaceuticals, Inc. SEC filings document the company's commercial rare-disease business, including ORLADEYO® results, revenue guidance, pricing disclosures, and financial results furnished on Form 8-K. The filings also describe pipeline and business-development matters involving HAE programs, including navenibart licensing and the completed acquisition of Astria Therapeutics as a BioCryst subsidiary.
BioCryst's filings further cover financing and capital-structure matters, including term-loan arrangements, as well as proxy disclosures on board elections, executive compensation, equity awards, committee structure, and shareholder voting matters. Material-event reports and proxy statements provide the formal record for governance changes, strategic transactions, and Regulation FD disclosures.
BioCryst Pharmaceuticals (Nasdaq: BCRX) filed an 8-K announcing a planned CEO transition. Incumbent President & CEO Jon Stonehouse will retire on 31 Dec 2025 after 17 years at the helm; he reports no disagreements and will stay on the board. He retains eligibility for his 2025 bonus and up to 18 months of subsidised health coverage.
The board named current Chief Commercial Officer Charlie Gayer (age 54) as President effective 1 Aug 2025 and as CEO effective 1 Jan 2026. Compensation terms include:
- 2025 base salary raised to $675k; annual incentive target blended at 70-75% of salary.
- From 2026: base salary $775k; AIP target set at 85% of salary.
- Severance (without cause / post-change-of-control): two years of salary, 2× target bonus over two years, and up to 12 months of subsidised health coverage.
The board will expand from nine to ten directors and elect Gayer to the new seat beginning 1 Jan 2026 (term ends 2028). No related-party transactions or disagreements were disclosed, and Gayer will initially serve on no board committees.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) filed an 8-K announcing a key leadership change. Effective 7 July 2025, the Board appointed Babar Ghias (46) as Chief Financial Officer, Principal Accounting Officer and Head of Corporate Development. Mr. Ghias brings two decades of healthcare and life-sciences experience, including CFO roles at AvenCell Therapeutics and Marathon Pharmaceuticals and M&A advisory work at Credit Suisse.
Compensation package includes: (i) base salary of $560,000; (ii) annual incentive target equal to 70 % of salary (full-year eligible for 2025); (iii) a $160,000 one-time cash bonus payable within 30 days; and (iv) Inducement Grants on 31 July 2025 of 147,000 RSUs and 305,000 stock options, vesting in four equal annual tranches from the first anniversary of grant.
The filing states Mr. Ghias has no related-party transactions, no special arrangements leading to his appointment, and no family relationships with existing directors or officers. A press release (Ex. 99.1) concurrently discloses the hire.
Investor take-away: While the event does not change current financial guidance, BioCryst strengthens its executive bench with a CFO possessing commercialisation and deal-making expertise that could support future capital strategy and business development.
BioCryst Pharmaceuticals (Nasdaq:BCRX) filed an 8-K announcing it has signed a definitive Stock Purchase Agreement dated June 27 2025 to sell 100% of the equity of BioCryst Ireland Ltd. and its subsidiaries to Neopharmed Gentili S.p.A.
No purchase price was disclosed, and closing is subject to customary regulatory approvals, financing by the buyer and other conditions. The company warns of possible business disruption, transaction costs and relationship changes during the interim period.
The press release is furnished as Exhibit 99.1; no pro-forma financials were included. Management makes forward-looking statements regarding timing, benefits and risks of the divestiture.
BioCryst Pharmaceuticals (NASDAQ:BCRX) announced that the FDA has extended the PDUFA goal date for their NDA regarding ORLADEYO oral granules for pediatric HAE patients aged 2-11 years. The 3-month extension moves the target action date to December 12, 2025. The extension was triggered by the company's submission of additional final reports and formulation data, which the FDA classified as a major amendment requiring full review.
The delay affects the potential expansion of ORLADEYO, currently approved for other age groups, into the pediatric hereditary angioedema market segment. The FDA requires additional time to review the supplementary data for safety and efficacy in young patients.